The Senate Health, Education, Labor and Pensions Committee advanced the nomination of Dr. Erica Schwartz to lead the Centers for Disease Control and Prevention (CDC) on July 30, despite Democratic concerns over her stance on vaccine policy. The committee voted 13-10 to send her nomination to the full Senate, with only Sen. Tim Kaine (D-VA) joining Republicans in support. Meanwhile, Sean Kaufman, Trump’s nominee for a pandemic preparedness agency at the Health and Human Services Department, advanced 12-11 with only Republican support.
Committee Chairman Bill Cassidy (R-LA) expressed pragmatic support for the nominees, stating, “Sometimes you don’t get the nominee that you’d like to have, but you get a nominee that you have to have if you’re going to address serious issues.” Schwartz, a former deputy surgeon general and Coast Guard chief medical officer, faced scrutiny during her July 15 confirmation hearing over whether she would resist pressure from HHS Secretary Robert F. Kennedy Jr. on vaccine policies. Democrats and Cassidy questioned her willingness to prioritize public health over political influence, citing the firing of her predecessor, Susan Monarez, for refusing to pre-approve reductions in the childhood vaccine schedule.
Background and Context
Schwartz has a long career in public health, including 24 years in the U.S. Public Health Service Commissioned Corps. Her nomination was initially delayed due to Sen. Lisa Murkowski’s (R-AK) absence. The full Senate, controlled by Republicans, will now vote on her confirmation. If approved, she would become the 22nd CDC director, overseeing the agency’s efforts to combat preventable health threats.
Opposing Views on Vaccine Policy
Democrats and some Republicans raised concerns about Schwartz’s ability to resist political interference in vaccine promotion. Cassidy, who lost his reelection bid partly due to clashes with Kennedy over vaccine policy, supported her nomination despite reservations. The committee’s vote reflects broader tensions over the role of science in public health decision-making under the Trump administration.